These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 15340386)

  • 21. Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era.
    Evans BJ
    Clin Pharmacol Ther; 2010 Dec; 88(6):749-51. PubMed ID: 21081943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
    Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
    Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The drug diagnostic co-development concept paper: commentary from the 3rd FDA-DIA-PWG-PhRMA-BIO Pharmacogenomics Workshop.
    Hinman LM; Huang SM; Hackett J; Koch WH; Love PY; Pennello G; Torres-Cabassa A; Webster C
    Pharmacogenomics J; 2006; 6(6):375-80. PubMed ID: 16652120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory approval for new pharmacogenomic tests: a comparative overview.
    Joly Y; Koutrikas G; Tassé AM; Issa A; Carleton B; Hayden M; Rieder MJ; Ramos-Paque E; Avard D
    Food Drug Law J; 2011; 66(1):1-24, i. PubMed ID: 24505844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What will it take to reap the clinical benefits of pharmacogenomics?
    Evans BJ
    Food Drug Law J; 2006; 61(4):753-94. PubMed ID: 17180771
    [No Abstract]   [Full Text] [Related]  

  • 26. Implications of pharmacogenomics for drug development.
    Kirk RJ; Hung JL; Horner SR; Perez JT
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integration of pharmacogenetics and pharmacogenomics in drug development: implications for regulatory and medical decision making in pediatric diseases.
    Piana C; Surh L; Furst-Recktenwald S; Iolascon A; Jacqz-Aigrain EM; Jonker I; Russo R; van Schaik RH; Wessels J; Della Pasqua OE
    J Clin Pharmacol; 2012 May; 52(5):704-16. PubMed ID: 21566202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measuring the value of pharmacogenomics.
    Phillips KA; Van Bebber SL
    Nat Rev Drug Discov; 2005 Jun; 4(6):500-9. PubMed ID: 15915153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenomics: a new clinical or regulatory paradigm? European experiences of pharmacogenomics in drug regulation and regulatory initiatives.
    Prasad K; Breckenridge A
    Drug Discov Today; 2011 Oct; 16(19-20):867-72. PubMed ID: 21920454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop.
    Salerno RA; Lesko LJ
    Pharmacogenomics J; 2006; 6(2):78-81. PubMed ID: 16402087
    [No Abstract]   [Full Text] [Related]  

  • 31. FDA guidance on pharmacogenomics data submission.
    Savage DR;
    Nat Rev Drug Discov; 2003 Dec; 2(12):937-8. PubMed ID: 14756137
    [No Abstract]   [Full Text] [Related]  

  • 32. [Pharmacogenetics of anticancer drugs].
    de Chaisemartin L; Loriot MA
    Pathol Biol (Paris); 2005 Mar; 53(2):116-24. PubMed ID: 15708657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ethical and legal implications of pharmacogenomics.
    Rothstein MA; Epps PG
    Nat Rev Genet; 2001 Mar; 2(3):228-31. PubMed ID: 11256075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA pharmacogenomics guidance sends clear message to industry.
    Ratner M
    Nat Rev Drug Discov; 2005 May; 4(5):359. PubMed ID: 15902767
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacogenomics: an in-house advantage?
    Borchardt PE
    Drug Discov Today; 2006 Jan; 11(1-2):1-3. PubMed ID: 16478684
    [No Abstract]   [Full Text] [Related]  

  • 36. [Pharmacogenomics: the quest for individualized therapy].
    López-López M; Guerrero-Camacho JL; Familiar-López IM; Jung-Cook H; Corona-Vázquez T; Alonso-Vilatela ME
    Rev Neurol; 2004 Dec 1-15; 39(11):1063-71. PubMed ID: 15597270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetics and the concept of individualized medicine.
    Shastry BS
    Pharmacogenomics J; 2006; 6(1):16-21. PubMed ID: 16302022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An outsider's viewpoint: the FDA should regulate clinical pharmacogenetic/genomic tests, but...
    O'Kane D
    Clin Pharmacol Ther; 2010 Dec; 88(6):746-8. PubMed ID: 21081942
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacogenomics: history, barriers, and regulatory solutions.
    Blankstein S
    Food Drug Law J; 2014; 69(2):273-314, ii. PubMed ID: 25163212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenomics. Going from genome to pill.
    Service RF
    Science; 2005 Jun; 308(5730):1858-60. PubMed ID: 15976283
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.